A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US

Trial Profile

A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs TDENV PIV (Primary) ; AS03B
  • Indications Dengue
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 12 Oct 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
    • 12 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 15 Jun 2018.
    • 18 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top